Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05605548 · ClinicalTrials.gov registry record · Early Phase 1
Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)
A Early Phase 1 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
NCT05605548 is a Early Phase 1 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 4 participants.
The verdict
NCT05605548, a Early Phase 1 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Cardiovascular health is a critical problem in patients with chronic obstructive pulmonary disease (COPD). Existing literature suggests oxidative stress from the mitochondria c driving some of the poor health outcomes in COPD. MitoQ is a mitochondrial-targeted antioxidant that has shown promise in improving cardiovascular outcomes in similar populations. Thus the purpose of this study is to test if MitoQ can improve cardiovascular health in COPD.
Interventions
- OTHER Placebo
- DRUG MitoQ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-02-16 |
| Est. Completion | 2024-07-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05605548
The ClinicalTrials.gov registry entry for NCT05605548 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05605548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05605548 about?
NCT05605548 is a clinical study titled "Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)". Cardiovascular health is a critical problem in patients with chronic obstructive pulmonary disease (COPD). Existing literature suggests oxidative stress from the mitochondria c driving some of the poor health outcomes in COPD. MitoQ is a mitochondrial-targeted antioxidant that has shown promise in i...
What is the current status of trial NCT05605548?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2023-02-16. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT05605548?
The interventions under investigation include: Placebo (OTHER), MitoQ (DRUG).
Who is sponsoring clinical trial NCT05605548?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.